COMPUTEX-TAIPEI
28.5.2021 10:51:07 CEST | Business Wire | Press release
COMPUTEX 2021 Virtual organized by TAITRA will take place from May 31 to June 30 online. To keep the industry updated with the most groundbreaking technology trends and provide participants with a comprehensive vision of the world, COMPUTEX extended its keynote and forum speeches to top CEOs and senior executives from leading international companies such as AMD, Arm, Intel, Micron, NVIDIA, NXP Semiconductors, Qualcomm and Supermicro.
James Huang, TAITRA Chairman, pointed out that "COMPUTEX CEO Keynote has received great interest since its introduction in 2019. This year, COMPUTEX takes it a step further by leveraging the cross-industry capabilities of technology giants, providing a platform to share insights and exchange ideas in reshaping a post-pandemic future.”
Leading CEOs and Senior Executives of Tech Giants to Deliver Keynotes
Monday, May 31, at 10:00 AM (GMT+8)
Michelle Johnston Holthaus, Executive Vice President at Intel Corporation, will speak on the Innovation Unleashed
and welcome Intel’s Steve Long, corporate vice president of Client Computing Group Sales, and Lisa Spelman, corporate vice president and general manager of the Xeon and Memory Group, to outline how Intel innovations help expand human potential by expanding technology’s potential.
Monday, May 31, at 2:00 PM (GMT+8)
Arm CEO Simon Segars will give a keynote on Sparking the World’s Post-Pandemic Recovery
, analyzing how AI will accelerate tackling complex challenges surrounding climate change, security, and equitable access to technologies and connectivity, acting thus as a remarkable force for good.
Tuesday, June 1, at 10:00 AM (GMT+8)
Dr. Lisa Su, President and CEO of AMD, will present a keynote with the theme “AMD Accelerating – The High-Performance Computing Ecosystem”
, sharing the AMD vision for the future of computing and how AMD speeds up innovation with ecosystem partners to deliver a leadership product portfolio for innovative solutions.
Tuesday, June 1, at 10:00 AM (GMT+8)
Jeff Fisher, Senior Vice President of NVIDIA’s GeForce Business Unit and Manuvir Das, Head of Enterprise Computing at NVIDIA will discuss The Transformational Power of Accelerated Computing
, from Gaming to the Enterprise Data Center. They will present the massive opportunities that GeForce PC gaming represents for the Taiwan ecosystem and shifts driving the democratization of AI and how enterprises embrace them can thrive in the coming years.
Wednesday, June 2, at 9:00 AM (GMT+8)
Sanjay Mehrotra, President and Chief Executive Officer of Micron will focus his keynote on Innovation for the Data Economy: Why Today’s Infrastructure Innovation Brings Data to Life, Powering Insights for All
, opening for the AIoT Evolution session of the COMPUTEX Forum, and sharing Micron’s vision for how data transform modern life and creates new opportunities for memory and storage innovation.
Wednesday, June 2, 10:30 AM (GMT+8)
Supermicro President, CEO & Chairman of the Board, Charles Liang, will give a keynote on Performance Begins at the Edge for 5G and Intelligent IoT
, presenting Supermicro’s newest solutions as well as its future strategy.
Wednesday, June 2, 2:00 PM (GMT+8)
NXP Semiconductors President and CEO Kurt Sievers will deliver a keynote on How AI Can Empower Industries, IoT and Automotive Industry
, the opening session for the AI Empowerment of the COMPUTEX Forum by sharing NXP Semiconductors' development and plans in AI, broadening people’s imagination of intelligent places.
Thursday, June 3, 8:40 AM (GMT+8)
Qualcomm Senior Vice President and General Manager Alex Katouzian will speak on "5G and the Future of the PC
," where he will share his unique perspectives on how 5G and the Always on, Always Connected PC are shaping the future of computing to meet the needs of a more mobile society.
For more COMPUTEX CEO Keynote and show information, please check out the official COMPUTEX website:
https://virtual.computextaipei.com.tw/events/
For more updates：
COMPUTEX website: https://www.computextaipei.com.tw
InnoVEX website: https://www.innovex.com.tw/
About COMPUTEX TAIPEI (also called COMPUTEX):
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Virtual:
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX, Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnoVEXVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.
About TAITRA:
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210528005147/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom